Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
Spanish police and soldiers track boars, reinforce farm security amid swine fever outbreak - 2Presenting Nintendo's New Pastel Bliss Con Tones for Switch Gamers: 3 Smart Choices
- 3Oldest sequenced RNA reveals details about a mammoth’s final moments 40,000 years
- 4Pick Your Favored kind of sandwich
- 5Experience Is standing by: 10 Pleasant Setting up camp Areas to
- France will build a new aircraft carrier as it increases defense spending
- Manual for Famous Beverages 2024
- Instructions to Amplify Certifiable Experience While Chasing after an Internet Advertising Degree
- Find the Advantages of Careful Eating: Developing a Sound Connection with Food
- From Sea shores to Urban areas: Astonishing Worldwide Travel Objections
- US FDA unveils new pathway to approve personalized therapies
- Tablets: Upgrade Your Understanding Experience
- 5 Instructive Toy Brands for Youngsters
- The Solution to Defeating Tarrying: Systems for Expanded Efficiency
